The IMG-7289-CTP-102 study is a study of bomedemstat (IMG-7289) in patients with myelofibrosis who no longer benefit from or cannot tolerate ruxolitinib (Jakafi®). The initial treatment period with bomedemstat lasts for 24 weeks. Participants are required to visit the clinic about 15 times during this treatment period. Visits are weekly for the first 8 weeks, then every 2 weeks for the next 8 weeks and then every month for the last 8 weeks.
There will be regular physical examinations and laboratory tests such as blood counts. In addition, there will be abdominal imaging (an MRI, or CT, as applicable) to measure spleen volume before you start taking bomedemstat and again at Weeks 12 and 24 of treatment. Bone marrow samples will also be collected before you start taking bomedemstat and at Week 24 of treatment.
If participants are receiving clinical benefit from treatment with bomedemstat at the end of 24 weeks of treatment, they may continue to receive bomedemstat for an additional 24 weeks.